OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials
Ze Chen, Gerui Li
Clinical Drug Investigation (2019) Vol. 39, Iss. 6, pp. 521-531
Closed Access | Times Cited: 22
Ze Chen, Gerui Li
Clinical Drug Investigation (2019) Vol. 39, Iss. 6, pp. 521-531
Closed Access | Times Cited: 22
Showing 22 citing articles:
Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes
Caiyan Zou, Xuekui Liu, Yiquan Sang, et al.
Medicine (2019) Vol. 98, Iss. 49, pp. e18245-e18245
Open Access | Times Cited: 73
Caiyan Zou, Xuekui Liu, Yiquan Sang, et al.
Medicine (2019) Vol. 98, Iss. 49, pp. e18245-e18245
Open Access | Times Cited: 73
Effect of empagliflozin in peripheral diabetic neuropathy of patients with type 2 diabetes mellitus
Sahar Mohamed El-Haggar, Yasser Mostafa Hafez, Amira Mohamed El Sharkawy, et al.
Medicina Clínica (2024) Vol. 163, Iss. 2, pp. 53-61
Closed Access | Times Cited: 5
Sahar Mohamed El-Haggar, Yasser Mostafa Hafez, Amira Mohamed El Sharkawy, et al.
Medicina Clínica (2024) Vol. 163, Iss. 2, pp. 53-61
Closed Access | Times Cited: 5
Therapeutic Potential of Various Intermittent Fasting Regimens in Alleviating Type 2 Diabetes Mellitus and Prediabetes: A Narrative Review
Sthembiso Msane, Andile Khathi, Aubrey Mbulelo Sosibo
Nutrients (2024) Vol. 16, Iss. 16, pp. 2692-2692
Open Access | Times Cited: 4
Sthembiso Msane, Andile Khathi, Aubrey Mbulelo Sosibo
Nutrients (2024) Vol. 16, Iss. 16, pp. 2692-2692
Open Access | Times Cited: 4
<p>SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients</p>
André Scheen
Diabetes Metabolic Syndrome and Obesity (2020) Vol. Volume 13, pp. 2765-2779
Open Access | Times Cited: 29
André Scheen
Diabetes Metabolic Syndrome and Obesity (2020) Vol. Volume 13, pp. 2765-2779
Open Access | Times Cited: 29
Sulphonylureas in the management of type 2 diabetes: To be or not to be?
André Scheen
Diabetes Epidemiology and Management (2021) Vol. 1, pp. 100002-100002
Open Access | Times Cited: 22
André Scheen
Diabetes Epidemiology and Management (2021) Vol. 1, pp. 100002-100002
Open Access | Times Cited: 22
Therapeutic Potential of Various Intermittent Fasting Regimens in Alleviating Type 2 Diabetes Mellitus and Prediabetes: A Comprehensive Review
Sthembiso Msane, Andile Khathi, Aubrey Mbulelo Sosibo
(2024)
Open Access | Times Cited: 3
Sthembiso Msane, Andile Khathi, Aubrey Mbulelo Sosibo
(2024)
Open Access | Times Cited: 3
Metformin-Insulin versus Metformin-Sulfonylurea Combination Therapies in Type 2 Diabetes: A Comparative Study of Glycemic Control and Risk of Cardiovascular Diseases in Addis Ababa, Ethiopia
Desye Gebrie, Tsegahun Manyazewal, Dawit A. Ejigu, et al.
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 3345-3359
Open Access | Times Cited: 18
Desye Gebrie, Tsegahun Manyazewal, Dawit A. Ejigu, et al.
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 3345-3359
Open Access | Times Cited: 18
Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States
Julie Z. Zhao, Eric D. Weinhandl, Angeline M. Carlson, et al.
Kidney Medicine (2022) Vol. 4, Iss. 8, pp. 100510-100510
Open Access | Times Cited: 12
Julie Z. Zhao, Eric D. Weinhandl, Angeline M. Carlson, et al.
Kidney Medicine (2022) Vol. 4, Iss. 8, pp. 100510-100510
Open Access | Times Cited: 12
Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70)
Shinichiro Shirabe, Katsuya Yamazaki, Mariko Oishi, et al.
Journal of Diabetes Investigation (2022) Vol. 14, Iss. 1, pp. 75-80
Open Access | Times Cited: 12
Shinichiro Shirabe, Katsuya Yamazaki, Mariko Oishi, et al.
Journal of Diabetes Investigation (2022) Vol. 14, Iss. 1, pp. 75-80
Open Access | Times Cited: 12
Effects of different doses of metformin on bone mineral density and bone metabolism in elderly male patients with type 2 diabetes mellitus
Lin-Xia Wang, Guangya Wang, Na Su, et al.
World Journal of Clinical Cases (2020) Vol. 8, Iss. 18, pp. 4010-4016
Open Access | Times Cited: 18
Lin-Xia Wang, Guangya Wang, Na Su, et al.
World Journal of Clinical Cases (2020) Vol. 8, Iss. 18, pp. 4010-4016
Open Access | Times Cited: 18
Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials
Desye Gebrie, Desalegn Getnet, Tsegahun Manyazewal
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 14
Desye Gebrie, Desalegn Getnet, Tsegahun Manyazewal
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 14
Associations between second‐line glucose‐lowering combination therapies with metformin and HbA1c , body weight, quality of life, hypoglycaemic events and glucose‐lowering treatment intensification: The DISCOVER study
Kamlesh Khunti, B Charbonnel, Andrew Cooper, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 8, pp. 1823-1833
Open Access | Times Cited: 12
Kamlesh Khunti, B Charbonnel, Andrew Cooper, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 8, pp. 1823-1833
Open Access | Times Cited: 12
Gustavo Akerman Augusto, Nicolle Cassola, Patrícia Médici Dualib, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 10, pp. 2289-2302
Closed Access | Times Cited: 12
Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis
SuA Oh, Sujata Purja, Hocheol Shin, et al.
Diabetes and Vascular Disease Research (2022) Vol. 19, Iss. 3
Open Access | Times Cited: 7
SuA Oh, Sujata Purja, Hocheol Shin, et al.
Diabetes and Vascular Disease Research (2022) Vol. 19, Iss. 3
Open Access | Times Cited: 7
The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for metformin: a systematic review and meta-analysis of randomized controlled trials
Xianzhi Li, Qianping Zhang, Xiaojun Zhou, et al.
Aging (2021) Vol. 13, Iss. 9, pp. 12748-12765
Open Access | Times Cited: 9
Xianzhi Li, Qianping Zhang, Xiaojun Zhou, et al.
Aging (2021) Vol. 13, Iss. 9, pp. 12748-12765
Open Access | Times Cited: 9
Systematic Review of the Economic Evaluation of Sodium–Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure
Kyung-ae Nam, D. Cho, Hyun-Ji Kim, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 7, pp. 463-474
Closed Access | Times Cited: 3
Kyung-ae Nam, D. Cho, Hyun-Ji Kim, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 7, pp. 463-474
Closed Access | Times Cited: 3
Is it time to ban sulfonylureas?
Antonio Ceriello
Journal of Diabetes (2020) Vol. 12, Iss. 11, pp. 848-850
Open Access | Times Cited: 7
Antonio Ceriello
Journal of Diabetes (2020) Vol. 12, Iss. 11, pp. 848-850
Open Access | Times Cited: 7
Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study
Bogdan Vlacho, Manel Mata‐Cases, Xavier Mundet, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 7
Bogdan Vlacho, Manel Mata‐Cases, Xavier Mundet, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 7
Effect of empagliflozin in peripheral diabetic neuropathy of patients with type 2 diabetes mellitus
Sahar Mohamed El-Haggar, Yasser Mostafa Hafez, Amira Mohamed El Sharkawy, et al.
Medicina Clínica (English Edition) (2024) Vol. 163, Iss. 2, pp. 53-61
Closed Access
Sahar Mohamed El-Haggar, Yasser Mostafa Hafez, Amira Mohamed El Sharkawy, et al.
Medicina Clínica (English Edition) (2024) Vol. 163, Iss. 2, pp. 53-61
Closed Access
Cardiovascular safety and efficacy of combination therapy with metformin and sodium-glucose cotransporter-2 inhibitors versus metformin and sulfonylureas in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Desye Gebrie, Desalegn Getnet, Tsegahun Manyazewal
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 1
Desye Gebrie, Desalegn Getnet, Tsegahun Manyazewal
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 1
Sodium-glucose cotransporter-2 inhibitors: updated evidence on their efficacy and safety in patients with type-2 diabetes
Vipul Gupta, Girish Khurana
International Journal of Basic & Clinical Pharmacology (2020) Vol. 9, Iss. 4, pp. 666-666
Open Access
Vipul Gupta, Girish Khurana
International Journal of Basic & Clinical Pharmacology (2020) Vol. 9, Iss. 4, pp. 666-666
Open Access
Existe-t-il encore une place pour les sulfamides hypoglycémiants dans le traitement du diabète de type 2 en 2021 ?
André Scheen
Médecine des Maladies Métaboliques (2020) Vol. 15, Iss. 1, pp. 45-52
Closed Access
André Scheen
Médecine des Maladies Métaboliques (2020) Vol. 15, Iss. 1, pp. 45-52
Closed Access
